{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009089","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.700366+00:00","generated_at":"2026-06-17T14:38:28.139881+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TRxADE HEALTH reports 16% revenue growth to $11.4M for FY2022; net loss narrows","bullets":["Revenue $11.4M (+16% YoY); net loss narrowed to ($3.9M) from ($5.3M) in 2021.","EPS ($0.41) per basic/diluted share vs ($0.65) prior year.","Adjusted EBITDA improved to ($0.09M) from ($3.1M) in 2021.","Added 1,212 new registered members; total ~14,400 on TRxADE platform.","Trxade Prime revenue up 46% YoY; Community Specialty down 29%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009089","json":"https://secwatch.observer/filing/0001493152-23-009089.json","markdown":"https://secwatch.observer/filing/0001493152-23-009089.md","text":"https://secwatch.observer/filing/0001493152-23-009089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223009089/0001493152-23-009089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223009089/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:38:28.139881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b798b3dcd44e1fa0c2ad86cf09e0dc640b674bfc","claim":"Scienture Holdings, Inc. reported the year ended December 31, 2022 results: revenue $11.4 million, net income ($3.9) million, EPS ($0.41) per basic and diluted share outstanding.","evidence_excerpt":"Consolidated revenues for the fiscal year of 2022 compared to the fiscal year of 2021 increased 16% to $11.4 million, compared to $9.9 million, respectively. The increase in consolidated revenue was driven by improved revenue attributed to our TRxADE Platform and Trxade Prime subsidiaries. The revenues generated by the TRxADE Platform in the fiscal year 2022 compared to 2021 increased 10% and Trxade Prime year over year revenue improved 46% in 2022 compared to 2021. The subsidiary company Community Specialty Pharmacy experienced a 29% decrease in revenue for the fiscal year 2022 compared to 2021. Gross profit analysis of comparable fiscal periods of 2022 and 2021 reflect an increase in gross profits of $0.7 million for the fiscal year of 2022 compared to 2021. As a percent of revenue, consolidated gross profit remained consistent at 48% for the comparable annual periods of 2022 and 2021. Operating expenses for the fiscal year of 2022 were $9.9 million, compared to $10 million in the fi","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223009089/0001493152-23-009089-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$11.4 million"},{"label":"Net income","value":"($3.9) million"},{"label":"EPS","value":"($0.41) per basic and diluted share outstanding"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}